Meeting
2017 ASCO Annual Meeting
PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA‑4 refractory melanoma.
Authors
Aung Naing
Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX
Aung Naing , Deborah Jean Lee Wong , Jeffrey R. Infante , Manish R. Patel , Shubham Pant , Bartosz Chmielowski , Filip Janku , Coya Tapia , Navneet Ratti , Peter Van Vlasselaer , Gail Linda Brown , Annie Hung , Martin Oft , Adi Diab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Other
Clinical Trial Registration Number
NCT02009449
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3084)
DOI
10.1200/JCO.2017.35.15_suppl.3084
Abstract #
3084
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer.
First Author: Aung Naing
Poster
2016 ASCO Annual Meeting
Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1.
First Author: Aung Naing
Poster
2017 ASCO Annual Meeting
Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC.
First Author: Deborah Jean Lee Wong
Poster
2018 Gastrointestinal Cancers Symposium
Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
First Author: J. Randolph Hecht